Bayer signs €50m deal for Orion's prostate cancer drug
This article was originally published in Scrip
Executive Summary
Bayer is paying €50m upfront to Finland's Orion for ODM-201, its prostate cancer drug, which is due to start a Phase III trial later this year.
You may also be interested in...
Bayer Sees Room For Third-To-Market Darolutamide In Prostate Cancer
ASCO GU: Darolutamide is important for the company's oncology portfolio, but does it have enough to compete against J&J's Erleada and Pfizer/Astellas' Xtandi?
Positive Phase III For Darolutamide In Prostate Cancer Could Improve Options For Orion
Top-line results from the Phase III ARAMIS study indicate the next-generation oral androgen receptor antagonist, darolutamide, has met its primary endpoint and could provide a boost for Finland's multinational and now pure-play pharma company, Orion, plus Bayer too.
WuXi eases CAR-T manufacturing burden with new US plant
China's WuXi PharmaTech, an R&D technology company serving the pharmaceutical, biotechnology and medical device industries, has announced construction of a new manufacturing facility in Philadelphia, US designed for cell therapy products, including chimeric antigen receptor T-cell (CAR-T) therapies. More manufacturing power is crucial to the success of this burgeoning, high-potential field.